Single-Cell tech could unlock secrets of a highly effective vaccine

NCT ID NCT03458780

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This pilot study tests a new technology called inDrop RNA-Seq to analyze individual immune cells in detail. Researchers will use it to study how healthy adults respond to the yellow fever vaccine, which is known to be very effective. The goal is to identify the specific cell types and genes that drive a strong immune response, which could help improve future vaccines.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
yellow fever vaccine (YF-Vax)
What this could lead to
If successful, this could reveal which cell types and genes are key for a strong vaccine response, potentially guiding better vaccine design.
What could go wrong
This is a very small pilot study with only 6 participants, so findings may not apply broadly. The technology is also new and unproven for this purpose.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

6 people

The number who actually took part.

Started

Aug 2016

Finished

Sep 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Healthy Volunteers

Ages

18 to 59 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female between the ages of 18 and 59 years old * Volunteers who have not received a vaccination within 30 days of the YFV and do not anticipate to receive a vaccination within 30 days * Volunteers who are seeking the YFV for either travel reasons or occupational risk * Volunteers willing to undergo one screening visit, one visit to receive the YFV, and four post-vaccination visits * Volunteers without medical conditions who are willing to give blood once for the development of the inDrop technique Exclusion Criteria: * Male or females under 18 or over 59 years of age * Volunteers who received other vaccination less than 30 days prior to receiving the YFV * Volunteers with acute or febrile disease * Volunteers unable to return for the post vaccination follow-up visits * Volunteers with an allergy to eggs, chicken proteins, gelatin, or other components of the Yellow Fever vaccine * Participation in another clinical study of an investigational product currently or within the past 90 days, or expected participation during this study * Is pregnant or lactating * Volunteers with a history of yellow fever vaccination and/or infection * Volunteers with a history of viral hepatitis and/or non-viral liver disease * In the opinion of the investigators, the volunteer is unlikely to comply with the study protocol * Immunosuppressed individuals as a result of cancer, transplantation, and or primary immunodeficiency * Immunosuppressed individuals as a result of medications (such as high-dose systemic corticosteroids, alkylating drugs, antimetabolites, TNF-α inhibitors (e.g., etanercept), IL-1 blocking agents (e.g., anakinra), and other monoclonal antibodies targeting immune cells (e.g.,rituximab, alemtuzumab) and/or radiation * Volunteers with thymus disorders (including myasthenia gravis, Di George syndrome, or thymoma) and/or history of thymectomy * Individuals infected with HIV

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The Rockefeller University

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.